Publix recalls GreenWise baby food pouches due to potential lead contamination
The recalled product is the 4-ounce GreenWise Pear, Kiwi, Spinach & Pea Baby Food pouch, with a 'Best if Used By' date of November 1, 2025, and GTIN 41415-00901. These pouches were sold in Publix stores across eight states: Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina, Virginia, and Kentucky.
Lead exposure is particularly concerning for infants and young children, as it can affect brain development and lead to learning and behavior problems. Even small amounts can be harmful, and symptoms may not be immediately apparent. If you suspect your child has been exposed to lead, consult your pediatrician about a blood test.
Related: Fat Brain Toys recalls rollers tile toys due to magnet ingestion hazard
If you have purchased the affected baby food pouch:
Do not feed it to your child.
Return the product to your local Publix store for a full refund.
For additional information, you can contact Publix Customer Care at 1-800-242-1227 or visit their website at publix.com.
This recall underscores the importance of staying informed about the products we provide to our children. Regularly checking for recalls and understanding potential risks can help ensure the health and safety of your family.
For more information on product recalls and safety tips, visit the U.S. Food and Drug Administration's website.
Related: Popular child carriers recalled due to fall hazard — what parents need to know
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13-07-2025
- Yahoo
The Big Squeeze: A behind-the-scenes look at reporting the decimation of Florida citrus
Florida once was the cornerstone of the most important meal of the day. How could breakfast be complete without a tall glass of orange juice? And more so, how could a tall glass of orange juice be complete without Florida oranges? Today, however, Florida grows a mere fraction of the oranges it historically once did. TCPalm business reporter Jack Randall wanted to find out why. He spent months talking to experts, and analyzed more than a century's worth of citrus data. I love orange juice (preferably without pulp), and ever since moving to the Treasure Coast, I've taken a liking to grapefruit, too. The Treasure Coast is considered by many to grow the sweetest and juiciest grapefruit in the world. But if you walk through Publix or any other grocery store, you'll more often than not find oranges and grapefruit from California or from another country. If Florida citrus is so great, why are Florida fruits so hard to come by? I spoke with citrus industry professionals and academic researchers. They pointed to the same devastating root cause — citrus greening. It's a highly infectious disease that diminishes crop yields and ultimately kills citrus plants. I combed through some of the first newspaper clippings and academic literature that reported on the bourgeoning agricultural epidemic. It first cropped up 20 years ago in South Florida. The disease — which is carried by an invasive insect — spread county-to-county, then nationwide. I analyzed decades of data from the Florida Department of Agriculture and Consumer Services. I plotted the number of oranges and grapefruit grown in Florida over the past century. You'll notice a dip for 2004-2005. During my research, a newspaper clipping caught my eye. It was one of the first media reports that contextualized the epidemic, with a tone that tried to remain optimistic. 'The apocalypse has not occurred," the Indian River Press Journal reported. "But the disease that results in bitter, misshapen fruit is said to be present in every grove to some extent.' But that article was from 2013. What about now, 20 years after citrus greening was first reported? How much citrus is grown in modern Florida? The answer is staggering — and a lot less than what I imagined. It's not all doom and gloom in the Sunshine State. Gene editing technology already has demonstrated promising results of fruit resisting citrus diseases. Florida grapefruit may one day be cultivated using CRISPR gene-splicing technology at the DNA level. Jack Randall is TCPalm's economy and real estate reporter. You can reach him at or 904-466-4755. This article originally appeared on Treasure Coast Newspapers: The Big Squeeze: A behind-the-scenes look at Florida's citrus decline
Business Wire
08-07-2025
- Business Wire
IMPLANET Announces Half-Year Revenue for 2025 up 41% to €5.8 Million
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, PEA-PME eligible), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the first half of 2025. Ludovic Lastennet, CEO of IMPLANET, said: "Following a second half of 2024 with strong growth of +66%, our excellent commercial performance continued into the first half of 2025, achieving growth of +41% compared to the same period last year. These results confirm the effectiveness of our strategy and underscore the full potential of our partnership with Sanyou Medical. Building on these results, we remain committed to accelerating the commercial rollout of our implant ranges across markets identified as strategic, particularly in the United States. Furthermore, we remain convinced that beyond the quality of our implant devices, now used daily in operating rooms, our range of equipment to assist surgeons represent one of the key pillars of our actual growth. Given the growing demand from surgeons and healthcare establishments for the deployment of innovative surgical tools, our partnership with Sanyou Medical enables us to look forward with confidence and determination to the next generation of AI-monitored cobotic and robotic surgical procedures." First-Half 2025 Revenue Growth of +41% The Company generated revenue of €5.81 million in the first half of 2025, compared to €4.12 million in the first half of 2024. This 41% growth in the first six months of 2025 confirms the strong performance recorded during the previous half-year, which saw a +66% increase. The Spine Implants business generated revenue of €3.99 million in the first half of 2025, compared to €3.64 million in 2024, representing a +10% increase versus the same period of the prior year. The medical equipment distribution business continues to grow strongly, driven by the ongoing deployment of the Olea ultrasound scalpel across all geographical areas, as well as by the development of the exclusive partnership with elliquence in the U.S. endoscopic spine surgery market. Medical equipment distribution revenue quadrupled in the first half of 2025 compared to the same period in 2024, reaching €1.82 million. Revenue in the United States for the first half of 2025 reached €1.58 million, compared to €0.58 million in the previous year, representing an increase of +174%, primarily driven by commercial developments with elliquence. In France, revenue grew by +5%, totaling €2.32 million. Export activity in the rest of the world also recorded strong growth of +44%, reaching €1.91 million in the first half of 2025 compared to €1.32 million in 2024. Second Quarter 2025 Revenue Growth of +71% The Spine Implants business recorded revenue of €1.88 million in the second quarter of 2025, representing a +12% increase compared to €1.68 million in the second quarter of 2024. Revenue from the medical equipment distribution activity reached €1.35 million in Q2 2025, compared to €0.21 million for the same period in 2024. Activity in France grew by +5%, reaching €1.16 million for the quarter compared to €1.11 million for the same period in 2024. In the United States, revenue was multiplied by 5.4x, rising to €1.25 million for Q2 2025, from €0.23 million in Q2 2024, driven in particular by commercial developments with elliquence. Export revenue in the Rest of the World reached €0.82 million in the second quarter of 2025, compared to €0.56 million in the prior year, representing an increase of +48%. Strategy and Outlook for 2025 Finalize the registration of existing products under the European Medical Device Regulation (MDR) and the FDA's 510(k). Continue to expand the Company's presence in the United States: Reinforce resources and commercial capabilities for the historical team; Expand the Company's direct approach by enlarging the scientific team of key opinion leaders; Enhance market momentum and expand the product offering: Deploy the commercial and technological partnership with Sanyou Medical for the joint development of a new, innovative European range of hybrid posterior fixation systems; Launch distribution of the JAZZ® platform in China, the world's largest spine market by volume, in collaboration with Sanyou Medical; Distribute advanced medical technology equipment in Europe, including the ultrasonic surgical scalpel from SMTP Technology Co. Position Implanet as a partner for surgeons and healthcare institutions in terms of Artificial Intelligence, cobotics and robotics adapted to our implants. Cash Position As of June 30, 2025, the Company had a cash position of €0.50 million. Additionally, during the second quarter of 2025, Implanet secured new financing in the form of a short-term working capital loan from Shanghai Pudong Development Bank ('SPD Bank') for a total amount of RMB 4.75 million, or approximately €0.57 million, with a term of 12 months, repayable in fine, without collateral and intended for payments to suppliers and other operating expenses, the repayment of which is guaranteed by Sanyou Medical. Considering this recent financing, the projected cash flow based on current business assumptions, the anticipated commercial developments for fiscal years 2025 and 2026, and the secured payment facilities with the Sanyou Medical group, the Company believes it will be able to meet its operational financing needs for the next twelve months. Additionally, the Company continues to explore various financing solutions to accelerate the development of its business and support medium-term growth. Upcoming Financial Communications First Half 2025 results – September 16 th, 2025, after market close About IMPLANET IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China's second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market's most advanced braided implant technology, JAZZ®. IMPLANET's orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris. For more information, visit ____________________________ 1 Unaudited figures
Business Wire
01-07-2025
- Business Wire
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis ® LCS
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, 'Median' or the 'Company'), manufacturer of eyonis ®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today it has filed an application for Class IIb CE marking of eyonis ® LCS (Lung Cancer Screening), its AI/ML tech-based Software as a Medical Device (SaMD) for computer aided detection and diagnosis (CADe/CADx) of lung cancer in screening programs. Concurrently to CE marking, Median has also applied for ISO 13485 certification for the Quality Management System supporting the manufacturing of eyonis ® LCS. Median Technologies applied for 510(k) clearance of eyonis ® LCS with the U.S. Food and Drug Administration (FDA) on May 2025. Both regulatory filings confirm that timetables for eyonis ® LCS are on track, towards commercial launch as soon as year-end 2025 in the U.S., pending FDA 510(k) clearance expected end Q3 2025, and in H1 2026 in Europe, pending Class IIb CE marking expected in Q1 2026. 'Filing for CE marking of eyonis ® LCS is yet another important step forward for Median, leveraging the Median eyonis ® strong technology, clinical development and regulatory capabilities,' s aid Fredrik Brag, CEO and Founder of Median Technologies. 'Our regulatory submissions are built on a significant volume of positive clinical data demonstrating eyonis ® LCS' safety and efficacy in REALITY and RELIVE successful pivotal studies. We are looking forward to continuing and finalizing our constructive discussions with market stakeholders, in both the U.S. and Europe, as we aim to bring eyonis ® LCS to patients eligible for lung cancer screening in existing and future screening programs. Thanks to multiple institutions visits and major medical congresses attendance, our eyonis ® team confirms the strong support of lung cancer key opinion leaders belonging to the pulmonology, oncology and radiology scientific bodies and societies in the U.S. and Europe. We are truly blessed with an exceptional appreciation of our highly differentiated technology, which contributes to establishing a powerful brand equity for eyonis ® LCS. Additionally, our device market access strategy is already developed, ready for execution in the U.S. and tailored for specific payers to ensure maximum market penetration'. Based on SOLACE project data, the overall eligible population in the EU is about 20 million people. Currently, Croatia and Poland have national Low Dose Computed Tomography (LDCT)-based lung cancer screening programs and many other European countries are conducting promising pilot programs. On June 23, 2025, LDCT-based lung cancer screening received green light in Germany for eligible people covered by statutory health insurance providers, with the policy due to go into effect in April 2026. Other European countries are moving toward lung cancer screening programs implementation, including France. In the U.S., the market opportunity includes a population of 14.5 million people, currently eligible for a LDCT lung cancer screening exam, with an existing potential reimbursement of $650 per exam with a SaMD postprocessing for characterization of malignant vs benign nodules. The eligible U.S. patient number is expected to rise in the coming years, driven by the planned broadening of the eligibility criteria. About eyonis ® LCS: eyonis ® Lung Cancer Screening (LCS) is an artificial intelligence AI-based computer aided detection and diagnosis (CADe/CADx) system, or Software as a Medical Device (SaMD) that uses machine learning to help analyze imaging data generated with low dose computed tomography (LDCT) to aid radiologists in diagnosis of lung cancer at the earliest stages, when it can still be cured in many patients. eyonis ® LCS has been the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY ( ID: NCT06576232) and RELIVE ( ID: NCT06751576), both of which have been successfully completed. Based on these pivotal data, Median Technologies submitted U.S. application for 510(k) clearance of eyonis ® LCS on May 13th, 2025, and European application for CE mark on June 30th, 2025. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis ®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit Forward-Looking Statements This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance. These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.
